1. Field of the Invention
This invention relates to sutures and methods of making the same.
2. Description of the Related Art
Sutures have been around for a long time, and are used by all medical professionals in many fields including orthopedics, cardiology, general surgery, neurological and neurovascular surgery. Sutures are made from raw materials including metals (e.g., Stainless, MP35N, Vitalium, gold, platinum), polymers (e.g., PET, PP, nylon, PE, PU, PGA, PLLA, PCL, PLA, PGA), collagen, and combinations of materials.
Sutures are either constructed from monofilaments of multifilament yarns. A suture can be either a stand along yarn (typically monofilament) or multiple yarns braided into a bigger structure.
The constituents of a suture (e.g., braid specs, polymer type, size of suture, lubricant used) define the handling properties of a yarn. Handling is defined by strength, flexibility, softness, ability to hold a knot, strength after a knot is applied, surface roughness, ability to slip through tissue, ability to slip a knot (like tying shoelaces), and many more. Most of these are defined and measured in USP codes or ASTM methods.
A multi-filament suture for biological use is disclosed. The suture has a warp yarn, a fill yarn, and the warp yarn and fill yarns are woven. The suture can have a sheath. The sheath can be woven. The sheath can be made from yarn and/or a solid formed material, such as a polymer or metal. The suture can have a core. The sheath can substantially surround the core. The yarns and/or sheath can elute agents, such as antibiotics and/or therapeutic pharmaceuticals that can aid healing.
A method for making a multi-filament suture for biological use is also disclosed. The suture is woven from at least one fill yarn and at least one warp yarn. The fill yarn can be tensioned. The method can include encompassing a core in a sheath. The method can include adding an agent to the suture, where the agent can elute from the suture.
The suture 2 can have a suture diameter 10. The suture diameter 10 can be from about 12 USP suture diameter to about 0 USP suture diameter. The suture diameter 10 can be constant relative to the longitudinal distance along the suture 2. The suture diameter 10 can change relative to the longitudinal distance along the suture 2. The change in the suture diameter 10 relative to the longitudinal distance along the suture can be one or more discrete (i.e., substantially instantaneous, immediate) changes and/or one or more lengths of continuous and/or increasing and/or decreasing change. The continuous and/or increasing and/or decreasing change in the suture diameter 10 can be gradual.
The tension in the fill yarns 8 can be adjusted to produce sutures 2 that can have different mechanical characteristics. When the tension in the fill yarns 8 is increased, the suture diameter 10 can decrease and the hardness of the suture 2, and the modulus of elasticity of the suture 2 can increase. The tension in the fill yarns 8 can be constant relative to the longitudinal distance along the suture 2. The tension in the fill yarns 8 can change relative to the longitudinal distance along the suture 2. The change in the tension in the fill yarns 8 relative to the longitudinal distance along the suture can be one or more discrete (i.e., substantially instantaneous, immediate) changes and/or one or more lengths of continuous and/or increasing and/or decreasing change. The continuous and/or increasing and/or decreasing change in the tension in the fill yarns 8 can be gradual.
One or more sets of core yarns 14 and/or sheath yarns 17 can be marker bands. The marker bands can be colored threads, radiopaque threads, yarns and/or systems (e.g., gold, platinum, iridium, rhenium, tantalum, or alloys and/or combinations thereof).
The suture can have one, two, three or more sheaths 16. Each sheath 16 can be on top or below (i.e., overlay) each other, and/or each sheath 16 can be at different longitudinal distances along the suture 2 from the other sheaths 16. Each sheath 16 can be interwoven with one or more other sheath 16 (e.g., by interweaving the sheath yarns 17).
Each set of core yarns 14 can have a core yarn length. Each sheath 16 can have a sheath length. Each sheath yarn 17 can have a sheath yarn length. The core yarn lengths and/or sheath lengths and/or sheath yarn lengths can be part or all of the length of the suture 2.
The suture 2 can have hollow lengths. The hollow length can be a length of the suture 2 that can have the sheath 16 and an absence of core yarns 16. For example, a single sheath 16 can have two or more sets of the core yarns 14 within the sheath 16, where a gap of no core yarns 14 exists in the sheath between two of the sets of core yarns 14. The hollow length can be part or all of the entire length of the suture 2.
The suture 2 can have exposed lengths. The exposed length can be a length of the suture 2 that can have one or more core yarns 16 and an absence of the sheath 16. For example, one or more core yarns 14 can have two or more sheaths 16 on the core yarns 14, where a gap of no sheath 16 exists on the core yarns 14 between two of the sheaths 16. The exposed length can be part or all of the entire length of the suture 2.
A port 22 can be formed between where the first strand 18 separates from the second strand 20 at the first composite strand 18, and where the first strand 18 comes together with the second strand 20 at the second composite strand 20. The port 22 can be used as a buttonhole. An end of the suture 2 or another suture can be pulled through the port 22 to form a knot. Other elements (e.g., elastic elements, needles) can be passed into the port 22 and attached to the suture 2. An object (e.g., another suture, catheter, staple, tube, guidewire, post) can be pulled or inserted through the port 22, and the first composite strand 18 and the second composite strand 20 can be twisted about the longitudinal axis 4 such that the first composite strand 18 and the second composite strand 20 can twist down onto the object, securing the object in the port 22.
The suture 2 can have a port 22 woven into the suture 2. The port 22 can be woven into the suture 2 as described supra. The port 22 can be woven into the suture 2 by leaving out a length of one or more fill yarns 8 and/or warp yarns 6.
The suture 2 can not come back together after furcating. For example, the suture 2 can have multiple strands extending from a composite strand, where the multiple strands have terminal ends away from the composite strand. The suture 2 can be driven into, for example, a tissue and/or medical device and multiple strands that can have terminal ends can extend from the tissue and/or medical device.
The first and/or second barbs 112 and/or 114 can be formed by weaving the suture 2 and then cutting one or more of the appropriate yarns (e.g., the specific core yarns 14 and/or sheath yarns 17). The first and/or second barbs 112 and/or 114 can be formed by making the suture 2 with multiple appropriate yarns of the correct length to terminate at the first and/or second barb 112 and/or 114.
A third barb 116 can be a yarn and/or a second suture, and/or a shaft of metal and/or polymer. The third barb 116 can be substantially straight. The third barb 116 can be releasably or fixedly attached (e.g., threaded, woven, adhered such as glued, welded), to the warp yarns 6 and/or the fill yarns 8. The third barb 116 can pass through a sheath 16 and/or be releasably or fixedly attached to the sheath yarns 17.
A fourth barb 118 can be curved. The fourth barb 118 can be releasably or fixedly attached to one or more warp yarns 6.
A fifth barb 120 can be curved. The curve of the fifth barb 120 can be, for example, from about 180 degrees to about 360 degrees, for example, about 345 degrees. about or more than about degrees. The fifth barb 120 can be releasably or fixedly attached to one or more warp yarns 6. The fifth barb 120 can be releasably or fixedly attached to the fill yarn 8. The fifth barb 120 can be configured to pass around the fill yarn 8, for example, so that the fill yarn 8 can retain the fifth barb 120 during use.
A sixth barb 122 can be curved. The curve of the sixth barb 122 can be, for example, about or more than about 360 degrees, for example about 540 degrees. The sixth barb 122 can be releasably or fixedly attached to one or more warp yarns 6. The sixth barb 122 can be releasably or fixedly attached to the fill yarn 8. The sixth barb 122 can be configured to pass around the fill yarn 8, for example, so that the fill yarn 8 can retain the sixth barb 122 during use.
The suture 2 can have any combination or single embodiment of barbs. The suture can have any number of barbs.
Any or all elements of the suture 2 and/or other devices or apparatuses described herein can be made from, for example, a single or multiple stainless steel alloys, nickel titanium alloys (e.g., Nitinol), cobalt-chrome alloys (e.g., ELGILOY® from Elgin Specialty Metals, Elgin, Ill.; CONICHROME® from Carpenter Metals Corp., Wyomissing, Pa.), nickel-cobalt alloys (e.g., MP35N® from Magellan Industrial Trading Company, Inc., Westport, Conn.), molybdenum alloys (e.g., molybdenum TZM alloy, for example as disclosed in International Pub. No. WO 03/082363 A2, published 9 Oct. 2003, which is herein incorporated by reference in its entirety), tungsten-rhenium alloys, for example, as disclosed in International Pub. No. WO 03/082363, polymers such as ultra-high molecular weight polyethylenes (e.g., DYNEEMA® from DSM, Heerlen, The Netherlands; SPECTRA® from Honeywell International, Inc., Morristown, N.J.; VECTRAN® from Celanese AG, Kroberg im Taunus, Germany) polyethylene teraphathalate (PET), polyester (e.g., DACRON® from E. I. Du Pont de Nemours and Company, Wilmington, Del.), polypropylene, (PET), polytetrafluoroethylene (PTFE), expanded PTFE (ePTFE), polyether ether ketone (PEEK), nylon, polyether-block co-polyamide polymers (e.g., PEBAX® from ATOFINA, Paris, France), aliphatic polyether polyurethanes (e.g., TECOFLEX® from Thermedics Polymer Products, Wilmington, Mass.), polyvinyl chloride (PVC), polyurethane, thermoplastic, fluorinated ethylene propylene (FEP), absorbable or resorbable polymers such as polyglycolic acid (PGA), polylactic acid (PLA), polycaprolactone (PCL), polyethyl acrylate (PEA), polydioxanone (PDS), and pseudo-polyamino tyrosine-based acids, extruded collagen, silicone, zinc, echogenic, radioactive, radiopaque materials, any of the other materials listed herein or combinations thereof. Examples of radiopaque materials are barium sulfate, zinc oxide, titanium, stainless steel, nickel-titanium alloys, tantalum and gold.
Any or all elements of the suture 2 and/or other devices or apparatuses described herein, can be or have a matrix for cell ingrowth or used with a fabric, for example a covering (not shown) that acts as a matrix for cell ingrowth. The matrix and/or fabric can be, for example, polyester (e.g., DACRON® from E. I. Du Pont de Nemours and Company, Wilmington, Del.), polypropylene, PTFE, ePTFE, nylon, extruded collagen, silicone or combinations thereof.
The elements of the suture 2 and/or other devices or apparatuses described herein and/or the fabric can be filled and/or coated with an agent delivery matrix known to one having ordinary skill in the art and/or a therapeutic and/or diagnostic agent. The agents within these matrices can include radioactive materials; radiopaque materials; cytogenic agents; cytotoxic agents; cytostatic agents; thrombogenic agents, for example polyurethane, cellulose acetate polymer mixed with bismuth trioxide, and ethylene vinyl alcohol; lubricious, hydrophilic materials; phosphor cholene; anti-inflammatory agents, for example non-steroidal anti-inflammatories (NSAIDs) such as cyclooxygenase-1 (COX-1) inhibitors (e.g., acetylsalicylic acid, for example ASPIRIN® from Bayer AG, Leverkusen, Germany; ibuprofen, for example ADVIL® from Wyeth, Collegeville, Pa.; indomethacin; mefenamic acid), COX-2 inhibitors (e.g., VIOXX® from Merck & Co., Inc., Whitehouse Station, N.J.; CELEBREX® from Pharmacia Corp., Peapack, N.J.; COX-1 inhibitors); immunosuppressive agents, for example Sirolimus (RAPAMUNE®, from Wyeth, Collegeville, Pa.), or matrix metalloproteinase (MMP) inhibitors (e.g., tetracycline and tetracycline derivatives) that act early within the pathways of an inflammatory response. Examples of other agents are provided in Walton et al, Inhibition of Prostoglandin E2 Synthesis in Abdominal Aortic Aneurysms, Circulation, Jul. 6, 1999, 48-54; Tambiah et al, Provocation of Experimental Aortic Inflammation Mediators and Chlamydia Pneumoniae, Brit. J. Surgery 88 (7), 935-940; Franklin et al, Uptake of Tetracycline by Aortic Aneurysm Wall and Its Effect on Inflammation and Proteolysis, Brit. J. Surgery 86 (6), 771-775; Xu et al, Sp1 Increases Expression of Cyclooxygenase-2 in Hypoxic Vascular Endothelium, J. Biological Chemistry 275 (32) 24583-24589; and Pyo et al, Targeted Gene Disruption of Matrix Metalloproteinase-9 (Gelatinase B) Suppresses Development of Experimental Abdominal Aortic Aneurysms, J. Clinical Investigation 105 (11), 1641-1649 which are all incorporated by reference in their entireties.
The suture 2 can be made from materials that can bioabsorb or otherwise erode, as known to those having ordinary skill in the art. The eroding sections can be specific yarns, lengths, diameters, depths, and/or surfaces of the suture 2. The suture 2 can deliver one or more agents at specific yarns, lengths, diameters, depths, and/or surfaces of the suture 2. The elasticity of the material of the suture 2 can change for specific yarns, lengths, diameters, depths, and/or surfaces of the suture 2.
The materials used to make the warp yarns 6 and/or the fill yarns 8 and/or the sheath 16 and/or any other element of the suture 2 or the suture 2 as a whole can be constant relative to the longitudinal distance along the suture 2. The materials used to make the warp yarns 6 and/or the fill yarns 8 and/or the sheath 16 and/or any other element of the suture 2 or the suture 2 as a whole can change relative to the longitudinal distance along the suture 2. The change in the materials used to make the warp yarns 6 and/or the fill yarns 8 and/or the sheath 16 and/or any other element of the suture 2 or the suture 2 as a whole relative to the longitudinal distance along the suture can be one or more discrete (i.e., substantially instantaneous, immediate) changes and/or one or more lengths of continuous and/or increasing and/or decreasing change. The continuous and/or increasing and/or decreasing change in the materials used to make the warp yarns 6 and/or the fill yarns 8 and/or the sheath 16 and/or any other element of the suture 2 or the suture 2 as a whole can be gradual.
The suture 2 can have additional elements, for example, metallic grommets, rivets, anchors, tubes, pins, spheres, combinations thereof. The additional elements can be woven into the suture 2.
The suture 2 can have different elements effecting the performance characteristics of the suture 2. Adjusting the type of material (e.g., polymer, metal), number of yarn ends and/or size of the yarn can effect the strength of the suture 2. Adjusting the material type (e.g., polymer) and/or density of the weave or yarns (i.e., a tighter, high density weave is smoother), can effect the knot slip of the suture 2. Adjusting the material type, density of weave or yarns, and/or if a polymer resides within the woven structure, where the polymer resides within the woven suture, can effect the knot strength of the suture 2. Adjusting the polymer type (e.g., mixing a soft polymer within the suture 2), and/or suture surface roughness, can effect knot retention of the suture 2. Weaving in a mix of various biodegrading polymers and/or changing the porosity of the suture can effect the long-term strength of the suture 2. The weave or yarn density and/or tension in the fill yarns 8 or warp yarns 6 can have an effect on stiffness in the suture 2. The polymer type, the crimp of the weave (i.e., high crimp is springier), the use of wrapped yarns (e.g., PET around Polyurethane), and/or the use of a partially oriented yarn (POY) can effect the elongation and/or elasticity of the suture 2.
The suture 2 can be configured to deform (e.g., dent) under pressure over the length of the suture 2 where the suture 2 is tied in a knot or otherwise frictionally restrained, for example, to improve knot retention. The core yarns 14 and/or sheath yarns 17 can be POY along the entire length of the core yarns 14 and/or sheath yarns 17, and/or along the length of the core yarns 14 and/or sheath yarns 17 where the suture 2 is tied in a knot or otherwise frictionally restrained. The suture 2 or elements thereof can be made from softer materials and/or a softer configuration (e.g., more porous, less dense weave) along the length of the suture 2 where the suture 2 is tied in a knot or otherwise frictionally restrained, compared to the materials and/or configuration for the remainder of the suture 2 or elements thereof. The suture 2 or elements thereof can have higher friction surface texturing along the length of the suture 2 where the suture 2 is tied in a knot or otherwise frictionally restrained, compared to the surface texturing for the remainder of the suture 2 or elements thereof.
The sheath 16 can be fixedly and/or releasably and/or slidably attached to the core 12 along all or part of the length of the suture 2. The sheath 16 can be fixedly and/or removably attach to the core 12 at attachment area 140. The attachment area 140 can be adjacent to the end of the suture 2. The sheath 16 at the attachment area 140 can be the failure zone for tensile stress on the sheath 16. The sheath 16 at the attachment area 140 can be perforated.
The exterior and/or interior of the sheath 16 can be low friction surfaces. The sheath 16 and/or a coating on the interior and/or exterior of the sheath 16 can be dissolvable. The exterior and/or interior and/or the entirety of the sheath 16 can have and/or be a coating. The coating can be an anti-microbial coating. The coating can be a lubricious coating. The lubricious coating can have or be a hydrogel. The coating can have or be any of the materials and/or agents described herein.
As disclosed herein, the transverse shape of the suture 2 can be adjusted (e.g., round to flat, flat to round). Adjusting the transverse sectional shape can optimize stress distributions, and reduce the maximum stresses on yarns in the suture 2. The transverse sectional shape can be adjusted without substantively affecting the strength of the suture 2.
The suture 2 can have a rough, open surface. The rough, open surface can promote tissue in-growth into the suture 2. If the suture 2 is directly molded into a part (e.g., injection molded), the suture 2 can have a bumpy surface to improve the bond strength between the part and the suture 2.
The yarn tension, number of yarns, position of the yarns, weave angle, size of the yarn, polymer type, number of the yarns running in the weave, mixing of yarn layers (e.g., changing through cross section binding or thru weaving systems), mixing of sheath and core, individual yarn tensions, sheath density versus core yarn density, core yarn density, changing density down the suture length, changing diameter down the suture length, and cross section shape down the suture length (e.g., round to flat, and back to round) can be adjusted by the elements and/or use alterations.
The suture 2 and/or any elements herein can be made from shape memory materials (e.g., Nitinol). Part or all of the suture 2 can be preshaped or otherwise preformed into a preformed suture configuration. During use the suture 2 can be deformed or the configuration of the suture otherwise altered. During use, the suture 2 can resiliently or otherwise return to the preformed suture configuration.
As used herein, configuration can refer to shape and/or size and/or other physical characteristics relating to structure.
It is apparent to one skilled in the art that various changes and modifications can be made to this disclosure, and equivalents employed, without departing from the spirit and scope of the invention. Elements shown with any embodiment are exemplary for the specific embodiment and can be used on other embodiments within this disclosure.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/US05/30345 | 8/26/2005 | WO | 00 | 3/25/2008 |
Number | Date | Country | |
---|---|---|---|
60605047 | Aug 2004 | US |